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Tenascin and oncofetal fibronectin - oncofetal markers or indicators of
extraceliular matrix remodelling?
Sir - We read with interest the study on 'Immunohisto-
chemical expression of tenascin in normal stomach tissue,
gastnc carcinomas and gastric carcinoma in lymph nodes'
recently published in British Journal of Cancer (Ikeda et al.,
1995). In this study Ikeda et al. observed that tenascin, which
is not expressed in the adult mucosal and submucosal
connective tissue of the stomach, is expressed in the fibrous
stroma surrounding foci of cancer in 41% of primary
tumours and 32% of lymph node metastases (Ikeda et al.,
1995). They also observed that tenascin expression did not
correlate with any of the parameters evaluated in the study,
namely the degree of differentiation, abundance of fibrous
stroma, depth of invasion, lymph node metastasis and
prognosis.
We concur that their results show that 'tenascin appears
during the process of either malignant transformation or
tumour progression' (Ikeda et al., 1995). This does not mean,
however, that one can assume that tenascin expression is
stnctly associated to the neoplastic condition per se.
Moreover, we think Ikeda et al. have not obtained sufficient
evidence to substantiate the assumption that 'the positive
expression of tenascin may be useful as a stromal marker for
the early detection of gastric cancer' (Ikeda et al., 1995).
Firstly, they did not study precursor lesions of gastric
carcinoma, either as isolated lesions or as lesions in the
periphery of carcinomas, and thus missed the first steps of
gastnc carcinogenesis. Secondly, they did not include in their
study the analysis of non-cancerous conditions that may
induce the expression of tenascin (e.g. peptic ulcers with
granulation tissue and marked remodelling of the connective
tissue).
We raise these issues because we found that the
aforementioned conditions may cause false-positive results
when dealing with markers with oncofetal potential, such as
the so-called oncofetal fibronectin (onf-FN), an isoform of
fibronectin that some authors claim to be specifically
associated with malignant transformation (Matsuura and
Hakomori, 1989; London-Rosa et al., 1990; Mandel et al.,
1992). At variance with fibronectin, which is widely
distributed in normal tissues and particularly prominent in
the granulation tissue ofulcerated areas ofgastric carcinomas
(David et al., 1994), onf-FN was thought to appear
exclusively in the stroma of cancers, thus leading to the
possibility of using its detection in the diagnosis of the initial
steps of carcinogenesis (Loridon-Rosa et al., 1990; Mandel et
al., 1992). This is not the case because, apart from its
presence in gastric carcinoma, we observed strong immuno-
staining for onf-FN at the base of the three peptic ulcers
included in our study (David et al., 1993). Our findings thus
show that the production of onf-FN is not strictly associated
with malignancy, being dependent on a variety of conditions
having in common the capacity to induce deposition and/or
remodelling of extracellular matrix. We wonder whether this
is also the case for the expression of tenascin.
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